In the CodeBreak 100 trial, two patients with NSCLC with baseline CDKN2A/B homozygous deletions and no treatment emerging alterations showed no response to sotorasib, but experienced disease progression,31 indicating primary resistance. Here, CDKN2A is linked to non-small cell lung carcinoma.